Elusys Therapeutics Finalizes HHS Contract to Deliver Anthim®, its Treatment for Inhalation Anthrax, to the U.S. Department of Health and Human Services

Media Center PRESS RELEASE 2022 ELUSYS THERAPEUTICS FINALIZES HHS CONTRACT TO DELIVER ANTHIM®, ITS TREATMENT FOR INHALATION ANTHRAX, TO THE U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Completed first phase of contract for $50 million; HHS options to procure up to $31 million of ANTHIM by the first half of 2023 Reaffirms ANTHIM as an […]

Obiltoxaximab receives marketing authorization from European Commission for the treatment of Inhalation Anthrax

Media Center PRESS RELEASE 2020 OBILTOXAXIMAB RECEIVES MARKETING AUTHORIZATION FROM EUROPEAN COMMISSION FOR THE TREATMENT OF INHALATION ANTHRAX PARSIPPANY, NJ, DECEMBER 2, 2020 – Elusys Therapeutics, Inc. (Elusys) today announced that the European Commission has approved obiltoxaximab, the company’s monoclonal antibody (mAb) anthrax antitoxin for the treatment of inhalation anthrax. Obiltoxaximab is indicated in all age groups […]

Obiltoxaximab receives positive CHMP opinion for the treatment of Inhalation Anthrax

Media Center PRESS RELEASE 2020 OBILTOXAXIMAB RECEIVES POSITIVE CHMP OPINION FOR THE TREATMENT OF INHALATION ANTHRAX European Commission Decision Anticipated in November 2020 PARSIPPANY, NJ, OCTOBER 8, 2020 – Elusys Therapeutics, Inc. (Elusys) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion recommending marketing […]

Elusys Therapeutics receives Health Canada approval for Anthim® for the treatment for Inhalation Anthrax

Media Center PRESS RELEASE 2020 ELUSYS THERAPEUTICS RECEIVES HEALTH CANADA APPROVAL FOR ANTHIM® FOR THE TREATMENT OF INHALATION ANTHRAX PARSIPPANY, NJ, AUGUST 12, 2020 – Elusys Therapeutics, Inc. (Elusys) today announced that Health Canada has approved the company’s New Drug Submission (NDS) for Anthim (obiltoxaximab for injection), the company’s monoclonal antibody (mAb) anthrax antitoxin for the treatment of […]

Elusys receives second delivery order from U.S. government for Anthim®, its treatment for Inhalation Anthrax

Media Center PRESS RELEASE 2018 ELUSYS RECEIVES SECOND DELIVERY ORDER FROM U.S. GOVERNMENT FOR ANTHIM®, ITS TREATMENT FOR INHALATION ANTHRAX Elusys receives $19.7 million for delivery of ANTHIM under first Delivery Order PINE BROOK, NJ, April 23, 2018 – Elusys Therapeutics, Inc. (Elusys) announced today that it has been awarded a $25.2 million follow-on Delivery […]

Elusys delivers first shipment of ANTHIM®, its treatment for Inhalational Anthrax, to U.S. Government Strategic National Stockpile

Media Center PRESS RELEASE 2017 ELUSYS DELIVERS FIRST SHIPMENT OF ANTHIM®, ITS TREATMENT FOR INHALATION ANTHRAX, TO THE U.S. GOVERNMENT STRATEGIC NATIONAL STOCKPILE Anthim Lyophilization Program Continues to Advance PINE BROOK, NJ, OCTOBER 10, 2017 – Elusys Therapeutics, Inc. (Elusys) announced today that the company has delivered the first doses of ANTHIM® (obiltoxaximab) Injection, its treatment […]

Elusys Receives $16.35 Million for Delivery of ANTHIM® to U.S. Government

Media Center PRESS RELEASE 2017 ELUSYS RECEIVES $16.35 MILLION FOR DELIVERY OF ANTHIM® TO U.S. GOVERNMENT ELUSYS awarded additional $5 million to complete development of novel lyophilized form of ANTHIM PINE BROOK, NJ, JANUARY 24, 2017 – Elusys Therapeutics, Inc. (Elusys) today announced it has received $16.35 million for completing the second delivery of ANTHIM®, (obiltoxaximab) Injection, its treatment for […]

Elusys Therapeutics Announces Publication of Data Establishing the Adult Human Dose for its Inhalational Anthrax Antitoxin ANTHIM® (Obiltoxaximab) Injection

Media Center PRESS RELEASE 2016 ELUSYS THERAPEUTICS ANNOUNCES PUBLICATION OF DATA ESTABLISHING THE ADULT HUMAN DOSE FOR ITS INHALATIONAL ANTHRAX ANTITOXIN, ANTHIM® (OBILTOXAXIMAB) INJECTION PINE BROOK, NJ, DECEMBER 20, 2016 – Elusys Therapeutics, Inc. (Elusys) today announced that the company published data and analyses used to determine the intravenous adult human dose for ANTHIM ®(obiltoxaximab) Injection, its treatment for […]

Elusys Therapeutics Announces Publication of Results from Five Clinical Trials with its Inhalational Anthrax Antitoxin ANTHIM® (Obiltoxaximab) Injection

Media Center PRESS RELEASE 2016 ELUSYS THERAPEUTICS ANNOUNCES PUBLICATION OF RESULTS FROM FIVE CLINICAL TRIALS WITH ITS INHALATIONAL ANTHRAX ANTITOXIN, ANTHIM®(OBILTOXAXIMAB) INJECTION PINE BROOK, NJ, SEPTEMBER 14, 2016 –  Elusys Therapeutics, Inc. (Elusys) today announced that the company published data on over 450 healthy adult subjects from five clinical trials used to support recent U.S. Food and […]

Elusys Therapeutics Announces that Manuscripts for its Anthrax Antitoxin, ANTHIM® (Obiltoxaximab) Injection, have been Accepted for Publication

Media Center PRESS RELEASE 2016 ELUSYS THERAPEUTICS ANNOUNCES THAT MANUSCRIPTS FOR ITS ANTHRAX ANTITOXIN, ANTHIM® (OBILTOXAXIMAB) INJECTION, HAVE BEEN ACCEPTED FOR PUBLICATION — Animal Efficacy Data for Treatment and Prophylaxis — PINE BROOK, NJ, JULY 20, 2016 – Elusys Therapeutics, Inc. (Elusys) today announced that two important manuscripts describing animal efficacy of ANTHIM (obiltoxaximab) Injection in treatment and prophylaxis of […]